InvestSMART

Pharmaxis Ltd (ASX: PXS) - Announcements

- Current share price for PXS : $0.027

ASX company news and announcements for Pharmaxis Ltd (PXS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pharmaxis Ltd (PXS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pharmaxis Ltd (PXS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pharmaxis Ltd (PXS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- IOC Endorses Aridol 28 Mar 2008 8:38AM $2.240 $0.027 fallen by 98.79%
- Pharmaxis` First Steps Into China 7 Mar 2008 11:21AM $2.420 $0.027 fallen by 98.88%
- Pharmaxis to Apply to Market Bronchitol in Australia 14 Feb 2008 3:01PM $2.950 $0.027 fallen by 99.08%
- Half Yearly Report and Accounts 11 Feb 2008 8:38AM $2.420 $0.027 fallen by 98.88%
- Appendix 4C - quarterly 25 Jan 2008 5:00PM $3.430 $0.027 fallen by 99.21%
- Pharmaxis Aridol Gains First Asian Approval 17 Jan 2008 10:28AM $3.600 $0.027 fallen by 99.25%
- Pharmaxis Appoints Portuguese Distributor for Aridol 14 Dec 2007 10:02AM $4.060 $0.027 fallen by 99.33%
- Aridol to be evaluated in major US asthma study 8 Nov 2007 11:21AM $4.390 $0.027 fallen by 99.38%
- Completion of FDA Special Protocol Assistance - CF 8 Nov 2007 11:03AM $4.390 $0.027 fallen by 99.38%
- Pharmaxis to Expand Manufacturing Capacity 2 Nov 2007 8:44AM $4.350 $0.027 fallen by 99.38%
- Appendix 4C - quarterly 25 Oct 2007 5:00PM $4.100 $0.027 fallen by 99.34%
- Pharmaxis Appoints Korean Distributor 18 Oct 2007 9:33AM $4.250 $0.027 fallen by 99.36%
- Share Placement and SPP 11 Oct 2007 9:50AM $4.080 $0.027 fallen by 99.34%
- Trading Halt 8 Oct 2007 6:07PM $4.280 $0.027 fallen by 99.37%
- Phase III Trial Finds Pharmaxis Bronchitol Effective 29 Aug 2007 9:00AM $3.870 $0.027 fallen by 99.30%
- Preliminary Final Report 10 Aug 2007 10:42AM $3.500 $0.027 fallen by 99.23%
- Appendix 4C - quarterly 31 Jul 2007 4:11PM $3.360 $0.027 fallen by 99.20%
- Pharmaxis Files for Aridol Approval in Korea 9 Jul 2007 11:24AM $3.190 $0.027 fallen by 99.15%
- Completes Phase III Bronchiectasis Trial 5 Jul 2007 12:25PM $3.200 $0.027 fallen by 99.16%
- Aridol Gains European Aproval 4 Jun 2007 9:42AM $3.520 $0.027 fallen by 99.23%
- First Patient Enrols in Aridol COPD Trial 15 May 2007 1:56PM $3.350 $0.027 fallen by 99.19%
- Commitments Test Entity - Third Quarter Report 19 Apr 2007 4:15PM $3.540 $0.027 fallen by 99.24%
- Begins Phase III Cystic Fibrosis Trial 11 Apr 2007 9:01AM $3.340 $0.027 fallen by 99.19%
- Pharmaxis Reports Phase II Results for Aridol in COPD 14 Mar 2007 9:04AM $3.220 $0.027 fallen by 99.16%
- Phase II Cystic Fibrosis Study Closes Enrollment 23 Feb 2007 9:10AM $3.270 $0.027 fallen by 99.17%

751 - 775 of 836 results

Page 31 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.